New hope for nerve disorder: testing different strengths of immune therapy
NCT ID NCT06752356
Summary
This study is testing two different doses of an immune globulin (antibody) therapy given through an IV to see which works better for maintaining control of CIDP, a chronic nerve disorder. About 161 adults with CIDP who currently depend on treatment will receive either a lower or higher dose every 3 weeks for 21 weeks. The main goal is to see if the higher dose helps more people improve their ability to function compared to the lower dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advanced Neurology Epilepsy and Sleep Center/ANESC Research
RECRUITINGEl Paso, Texas, 79912, United States
Conditions
Explore the condition pages connected to this study.